Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Status:
Terminated
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to administer a peptide vaccine in combination with
different adjuvants. Adjuvants are substances that may boost immune responses vaccines. In
this study, the adjuvants are Montanide ISA-51, polyICLC and cyclophosphamide. This study
will also evaluate the effects of the combination of the peptide vaccine and the adjuvants on
the immune system. The investigators will monitor these effects by performing tests in the
laboratory on participants' blood, a lymph node, and tissue from the sites of vaccination.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Craig L Slingluff, Jr
Collaborators:
Cancer Research Institute, New York City Ludwig Institute for Cancer Research